The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Alkermes plc (NASDAQGS: ALKS) securities between February 17, 2017 and November 1, 2018.
According to the Alkermes lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Alkermes you have until February 25, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.